RD07 in Patients With Advanced Claudin18.2+ Solid Tumors

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000038650

Enrollment

Unknown

Registered

2020-09-27

Start date

2021-01-16

Completion date

Unknown

Last updated

2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Claudin18.2+ Solid Tumors

Interventions

Case series:Treatment by RD07 cell infusion

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 70 years with pathologically/histologically confirmed diagnosis of adenocarcinoma of the stomach or gastroesophageal junction, or pancreatic adenocarcinoma; 2. Must have Claudin18.2+ tumor expression as determined by the Claudin18.2 IHC assay; 3. Failed or been intolerant of prior lines of systemic therapy; 4. Estimated life expectancy > 12 weeks; 5. At least 1 measurable lesion per RECIST 1.1; 6. ECOG performance status of 0~2.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. HBV, HCV, HIV or syphilis infection; 3. Any uncontrolled active infection; 4. Anticancer treatment within 2 weeks prior to leukapheresis; 5. Ever received any treatments targeting Claudin18.2; 6. History of alcoholism, drug abuse or mental illness;

Design outcomes

Primary

Measure	Time frame
Incidence of dose-limiting toxicities (DLTs);Incidence of treatment related adverse events (TRAEs);	—

Countries

China

Contacts

Public ContactYi Zhang

The First Affiliated Hospital of Zhengzhou University

yizhang@zzu.edu.cn+86 15138928971

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026